Aster Medcity, Kochi has moved to the front rank of Parkinson’s care in India with the introduction of Adaptive Deep Brain Stimulation (aDBS) at its Parkinson’s and Movement Disorders Centre, a development reported as the first such launch in the country. The move is significant because it builds on an already established DBS programme at Aster Medcity, where the hospital’s own official pages describe DBS as a key therapy for Parkinson’s disease patients whose symptoms are no longer adequately controlled by medication.
For patients with advanced Parkinson’s disease, conventional DBS has long been used to improve tremor, stiffness, slowness, and motor fluctuations by delivering electrical stimulation to specific brain targets. Aster Medcity’s official DBS page says the treatment can significantly improve motor symptoms, reduce dyskinesias, lower medicine burden in many cases, and improve quality of life. The hospital also describes Parkinson’s disease as the most common condition for which DBS is used in its programme.
What changes with adaptive DBS is that stimulation is no longer simply fixed and manually tuned at intervals. According to the launch report carrying Aster Medcity’s announcement, the new system can sense real-time brain signals linked to Parkinson’s symptoms and automatically adjust stimulation levels through the day and night within clinician-defined limits. In simple terms, instead of giving the same output regardless of what the patient is experiencing, the therapy becomes responsive to the patient’s moment-to-moment neurological state.
That technological jump mirrors the wider global shift in neuromodulation. Medtronic announced in January 2025 that its BrainSense adaptive DBS technology had received CE Mark approval in Europe, and in February 2025 the company said it had secured U.S. FDA approval for what it called the world’s first adaptive deep brain stimulation system for people with Parkinson’s. Medtronic said the system self-adjusts therapy in real time based on individual brain activity, positioning adaptive DBS as a major move toward more personalized, sensing-enabled treatment.
For Aster Medcity, this is not a sudden jump into an unfamiliar field. The hospital’s own 2022 announcement said Aster Medcity and India Medtronic had partnered to build a comprehensive and advanced DBS programme for Parkinson’s patients in India. That same official Aster announcement also highlighted the introduction of the NeuroNav MER system at Kochi, presented as a first in South Asia at the time, showing that the centre has been steadily building high-end movement-disorder intervention capability for several years.
Aster’s current official neurology and DBS pages further reinforce that positioning. The hospital describes its Kochi neurosciences centre as offering DBS surgery for Parkinson’s disease and other movement disorders, and one page explicitly refers to Aster Parkinson & Movement Disorders Centre as India’s most active center for DBS therapy for Parkinson’s disease in patient-story content hosted on its site. That background helps explain why the centre would be among the earliest in India to move toward adaptive DBS-enabled care.
If the reported launch translates into sustained clinical use, adaptive DBS could matter because Parkinson’s symptoms are not static across the day. They fluctuate with medication cycles, activity, fatigue, and sleep. A system that adjusts automatically has the potential to make therapy more precise, reduce periods of under- or over-stimulation, and give clinicians more refined control over long-term management. That is the promise now driving next-generation DBS worldwide, and Aster Medcity’s Kochi centre appears to be positioning itself squarely within that next phase
Reference:
You may also like
-
Ash Gourd in Ayurveda: The Strength of Kushmanda
-
Mukkutti (Biophytum sensitivum): A Small Herb with a Big Ayurvedic Presence
-
AFMS Doctors To Practise Across India Under New NMC Draft Rules
-
India Pushes Technology-Led Animal Health Overhaul Under One Health Framework
-
Alembic Pharma Secures USFDA Approval for Generic Methotrexate Injection
